Highlights

  • The Hydration Pharmaceuticals Company reported a narrower consolidated EBITDA loss for July and August 2026.
  • The company reported consolidated EBITDA loss of A$175,090 for the two-month period.
  • Hydralyte LLC recorded its first monthly EBITDA profit in August 2026 according to the company.
  • Gross Margin increased to 73.3% in August 2026 compared with the prior corresponding period.
  • The trading update did not provide Revenue figures, cash position or formal full-year guidance.

The Hydration Pharmaceuticals Company Limited (ASX:HPC) develops and markets oral rehydration products through its Hydralyte brand. The company’s latest trading update covers operating performance for July and August 2026, including changes in consolidated EBITDA, monthly results and gross margin performance.

Two-Month EBITDA Performance

The Hydration Pharmaceuticals Company reported a consolidated EBITDA loss of A$175,090 for the two months ended July and August 2026. This compared with a consolidated EBITDA loss of A$688,743 for the same period in 2025.

The company reported that the improvement reflected changes in its operating performance during the period. EBITDA excludes interest, tax, Depreciation and amortisation, meaning the update does not represent a statutory profit or loss result.

Monthly Operating Results

The company provided monthly comparisons for July and August 2026. Consolidated EBITDA was a loss of A$119,496 in July 2026 compared with a loss of A$370,679 in July 2025.

In August 2026, consolidated EBITDA loss narrowed to A$55,594 compared with a loss of A$318,064 in August 2025. The company also reported that Hydralyte LLC generated EBITDA of A$6,055 in August 2026, representing its first monthly EBITDA profit as described in the trading update.

Margin Development and Operating Factors

The company reported gross margin of 73.3% in August 2026, compared with 66.2% in August 2025. The trading update did not provide a detailed breakdown of the factors contributing to the margin change, including the impact of pricing, product mix or input costs.

Management attributed the improvement to restructuring the cost base and improving the underlying Economics of the Hydralyte business. These comments represent management’s explanation of the operational changes described in the announcement.

Information Not Included in the Update

The trading update focused on EBITDA and margin information for a two-month period. It did not provide revenue figures, cash balance details, funding position or a full financial performance assessment.

The company also noted that the reported figures had not been audited, examined or reviewed by independent auditors. Monthly operating figures can vary due to factors including shipment timing, promotional activity and seasonal Demand patterns.

Key Insights

The Hydration Pharmaceuticals Company’s latest update provides an operating performance indicator for the first two months of the 2026 period. The reported narrowing of EBITDA losses and the August Hydralyte LLC result provide additional information on recent operations, while broader financial performance will require consideration of future formal reporting.